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Abstract
Background: 3D domain swapping is a novel structural phenomenon observed in diverse set of protein structures
in oligomeric conformations. A distinct structural feature, where structural segments in a protein dimer or higher
oligomer were shared between two or more chains of a protein structure, characterizes 3D domain swapping. 3D
domain swapping was observed as a key mediator of numerous functional mechanisms and play pathogenic role
in various diseases including conformational diseases like amyloidosis, Alzheimer’s disease, Parkinson’s disease and
prion diseases. We report the first study with a focus on identifying functional classes, pathways and diseases
mediated by 3D domain swapping in the human proteome.
Methods: We used a panel of four enrichment tools with two different ontologies and two annotations database
to derive biological and clinical relevant information associated with 3D domain swapping. Protein domain
enrichment analysis followed by Gene Ontology (GO) term enrichment analysis revealed the functional repertoire
of proteins involved in swapping. Pathway analysis using KEGG annotations revealed diverse pathway associations
of human proteins involved in 3D domain swapping. Disease Ontology was used to find statistically significant
associations with proteins in swapped conformation and various disease categories (P-value < 0.05).
Results: We report meta-analysis results of a literature-curated dataset of human gene products involved in 3D
domain swapping and discuss new insights about the functional repertoire, pathway associations and disease
implications of proteins involved in 3D domain swapping.
Conclusions: Our integrated bioinformatics pipeline comprising of four different enrichment tools, two ontologies
and two annotations revealed new insights into the functional and disease correlations with 3D domain swapping.
GO term enrichment were used to infer terms associated with three different GO categories. Protein domain
enrichment was used to identify conserved domains enriched in swapped proteins. Pathway enrichment analysis
using KEGG annotations revealed that proteins with swapped conformations are present in all six classes of KEGG
BRITE hierarchy and significantly enriched KEGG pathways were observed in five classes. Five major classes of
disease were found to be associated with 3D domain swapping using functional disease ontology based
enrichment analysis. Five classes of human diseases: cancer, diseases of the respiratory or pulmonary system,
degenerative diseases of the central nervous system, vascular disease and encephalitis were found to be significant.
In conclusion, our study shows that bioinformatics based analytical approaches using curated data can enhance
the understanding of functional and disease implications of 3D domain swapping.
Keywords: Protein aggregation, Human disease, Deposition disease, Human proteome, Data integration, Biological
data mining
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Background
Computationally efficient classification, annotation and
prediction algorithms are rapidly improving our under-
standing of protein sequence-structure-function relation-
ships. Analysis of such relationships often helps in our
understanding of novel sequence or structural features in
the regulation of a particular function including molecu-
lar pathways and various disease mechanisms. Cells
attain its functional integrity with the help of molecular
mechanisms including protein-protein interactions [1-7].
Protein folding and subsequent oligomerization of pro-
tein chains help such interactions in cellular environ-
ment. Protein-protein interactions play a key role in
mediating higher order oligomerization. Protein-protein
interactions are diverse in nature and they can be broadly
classified, as transient interactions where the interactions
are weak and obligatory interactions that are permanent
in nature. Based on sequence homology, two proteins
with high degree of similarity could interact and form a
homodimer, where as two distantly related proteins
could form a heterodimer [8,9]. 3D domain swapping is a
unique protein structural mechanism observed in homo-
dimers or higher order oligomers with a specific type of
interaction, where a segment of two protein chains are
mutually swapped. 3D domain swapping was also
observed in protein structures in heteroligomer confor-
mations. 3D domain swapping was associated with sev-
eral proteins that were involved in diverse functional
events and disease pathways. Previous studies on 3D
domain swapping using structural properties indicated
that 3D domain swapping share similar structural fea-
tures of oligomeric protein complexes and primarily
associated with deposition diseases [10-13]. Prior studies
on 3D domain swapping were focused on small set of
proteins largely due to the unavailability of a curated
database of proteins involved in 3D domain swapping. In
this study, we present results from analysis of proteins in
the human genome and curated in 3DSwap knowledge-
base using multiple biological enrichment methods.
3DSwap is the first database that catalogued proteins
involved in 3D domain swapping. The database was
developed using a literature-based protein structural
curation strategy that utilized manual curation and a
structural bioinformatics pipeline to gather data pertain-
ing to 3D domain swapping. We used complete set of
human proteins from 3DSwap database and examined
statistically significant domains, biological process, cellu-
lar component, molecular function, biological pathways
and diseases using enrichment methods. From a bioinfor-
matics perspective, this manuscript is a case study that
leverage application of robust bioinformatics methods to
gain new functional and therapeutic insights from a pro-
tein structural mechanism.
3D domain swapping: Pathophysiological basis of
deposition diseases
3D domain swapping is a unique protein structural phe-
nomenon with implications in function, form and disease
(Figure 1). Only two scenarios (domain swapped dimer
and open-ended oligomeric swapping) of 3D domain
swapping are provided in the figure. Other scenarios like
double domain swapping, cyclic swapping and entirely
swapped structures were observed in proteins with
swapped oligomeric architecture. Protein structures
involved in 3D domain swapping is characterized by
hinge regions and swapped regions. 3D domain swapping
is associated with mutual swapping of a structural seg-
ment between two or more chains in a protein oligomer.
This mechanism was observed in a diverse group of pro-
teins that mediate different structural, functional and
physiological mechanisms. 3D domain swapping was pri-
marily defined as a mechanism for functional or struc-
tural oligomeric assembly, recently defined as the
molecular mechanism behind protein aggregation and
thus implicated as a pathogenic basis of diseases like
deposition diseases or conformational diseases [14], amy-
loidosis [15], serpinopathies [16] and proteinopathies
[16]. Proteins involved in such diseases have higher
aggregation propensities and involved in the formation of
highly specific aggregates of a single protein. From a
structural perspective, some of these aggregates were
generated by 3D domain swapping mechanism
[12-14,17-33]. From a clinical perspective, such diverse
disease manifestations mediated by this single structural
mechanism are of great interest. It still remains elusive
whether 3D domain swapping is exclusively associated
with such conformational diseases or they may also play
a crucial role in mediating complex diseases.
Dataset of human proteins involved in domain swapping
Irrespective of numerous biochemical and computational
studies focused on the molecular basis of 3D domain
swapping [11,34-52], a detailed account of functional
repertoire, including protein domains, Gene Ontology
(GO) terms, biological pathways and disease associated
with proteins in swapped conformation, were not
reported. The mechanism of 3D domain swapping was
reported in different evolutionary lineages and structures
in swapped conformation were identified in multiple
organisms with a large proportion characterized from
eukaryotes. Hitherto, proteome-wide analysis of this
unique structural mechanism was impossible due to the
non-availability of proteome level curated dataset.
Recently, we integrated in-depth literature curation and
structural bioinformatics analytics to curate proteins
involved in 3D domain swapping from Protein Data Bank
(PDB) and reported a knowledgebase of proteins involved
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in 3D domain swapping [53]. 3DSwap offers a compen-
dium of 293 protein structures with delineated hinge
regions, swapped regions and offers an ideal resource to
study functional and structural implications of domain
swapping.
Inference from biological and biomedical ontologies
using enrichment analysis
Enrichment analysis plays an important role in knowledge-
based bioinformatics approaches [54,55]. In this study,
enrichment analysis was performed using annotations
derived from Pfam domains [56], GO [57-59], KEGG
pathways [60] and Disease Ontology (DO) [61,62]. Enrich-
ment analysis in bioinformatics is a collective term refer-
ring to a group of statistical bioinformatics algorithms
developed to understand the global trends of a subset of
genes or gene products compared to a background popu-
lation (for example, all genes in the human genome and
whole proteins encoded in the entire human genome or
all genes tested in a given experiment or genes included in
gene expression platforms etc.). Huang et al. [54] sug-
gested a nomenclature to classify enrichment tools in
bioinformatics as singular enrichment analysis (SEA), gene
set enrichment analysis (GSEA) [63] and modular enrich-
ment analysis (MEA) [55]. Fundamental differences
between these three classes of algorithms arise in the man-
ner by which the enrichment P-value was calculated. In
SEA-based approach, annotation terms of subset of genes
were assessed one at a time against a list of background
genes. An enrichment p-value was calculated by compar-
ing the observed frequency of an annotation term with the
frequency expected by chance and individual terms
beyond the p-value cut-off (P-value ≤ 0.05). BiNGO [64],
FunctAssociate [65], Onto-express [66,67] are examples of
SEA-based enrichment analysis tools. GSEA approaches
are similar, but consider all genes during the enrichment
analysis, instead of a pre-defined threshold based genes, as
in SEA approach. For example, Gene Ontology terms are
connected by relationships and MEA based programs like
Ontologizer [68] and topGO [69] employ the relationships
Figure 1 Schematic representation of 3D domain swapping.
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that exist between the annotations. These programs were
reported to attain better sensitivity and specificity due to
the consideration of GO term relationships. GSEA is an
enrichment-based computational method to determine
whether an a priori defined set of genes show statistically
significant differences, when compared between two biolo-
gical states [63]. For example, a set of human genes differ-
entially regulated in a gene expression of analysis for a
particular type of cancer can be considered as a prior gene
list, and the background can be defined one or more data-
sets compiled in Molecular Signatures Database (MSigDB)
[70]. A variety of tools are currently available for the func-
tional enrichment analysis, a recent review cited 69 tools
for such analysis and the list of tools are rapidly growing.
Majority of these tools employ statistical methods using
Fisher’s test [71,72], hypergeometric function [64], bino-
mial test [72] or c2 tests [73] or combination of such
methods as implemented in tools like GFINDER [74] and
Onto-Express [66,67] for significant association of the GO
terms and the gene list with respect to the background
distribution. Concept of gene set enrichment analysis was
incorporated in to various programs that use biological or
functional annotations of genes and gene products to per-
form biological enrichment calculations using ontologies
and annotations. Gene Ontology enrichment and pathway
enrichment analysis employ similar conceptual and statis-
tical methods to understand functional and molecular
roles of subset of genes or proteins were found to be very
efficient in summarizing functional diversity or similarity
trends. Such approaches are routinely employed in gene
expression studies, high-throughput screening experi-
ments and genome-wide association studies (GWAS)
[75,76].
Gene ontology enrichment and pathway enrichment
analysis, using ontologies or annotations derived from a
subset of genes characterized from an experimental or
computational study, generally applied to infer new bio-
logical insights, which was otherwise impossible with
candidate gene-centric approaches. Due to the generic
nature of statistical methods used in enrichment analy-
sis, current set of enrichment algorithms and related
statistical methods can be used to infer enrichment
from annotation databases. Enrichment calculations are
currently available for various types of annotations.
Annotations of protein domains (Pfam [56], SMART
[77]), pathways (KEGG [60], GenMAPP[78]) and human
gene-disease associations using Online Mendelian
Inheritance in Man (OMIM) [79] are currently used for
enrichment analysis. Similar to GO, any ontology (for
example: disease ontology (DO) [62]) maintained by
Open Biological and Biomedical Ontologies (OBO) [80]
foundry or its mapping or derivatives (for example: dis-
ease-ontology (DOLite) [61]) can be effectively used for
enrichment analysis.
Enrichment tools, ontologies, annotation databases and
statistical methods
This study utilized four tools, two ontologies and two
annotation databases for inferring functional and disease
insights from list of human proteins involved in 3D
domain swapping. Protein domain enrichment was per-
formed using DAVID 6.7. Protein domain annotations
were derived from Pfam database, a database of evolutio-
narily conserved protein domain coordinates. Ontologi-
zer 2.0, a GO term enrichment tool with command-line
interface and improved statistical method for deriving
GO terms enriched in a given list of proteins was used in
this study. SubPathwayMiner, an R package that intern-
ally handles KEGG annotations for pathway enrichment
analysis were used to derive statistically significant path-
ways associated with the dataset. Enriched disease ontol-
ogy terms were identified using Functional Disease
Ontology server that consults Disease Ontology and it’s
derivative disease-ontology lite for identifying significant
diseases. H0 = List of curated proteins with swapped con-
formations are not associated with any class of protein
domains, gene ontology terms, KEGG pathways or dis-
ease ontology terms. We tested our null hypothesis indi-
vidually using four different tools and associated
annotations or ontologies. P-value from enrichment ana-
lyses were obtained using default statistical settings of
different tools employed in this study. Protein domain
enrichment P-values were derived from DAVID using a
modified Fisher Exact P-value, called EASE score [81].
GO term enrichment analysis P-values were derived
using Ontologizer 2.0 and corrected using Bonferroni
method [68]. KEGG pathway enrichment using Sub-
PathwayMiner, it provides False Discovery Rate (FDR)
corrected P-values. Disease enrichment analysis was per-
formed using Functional Disease Ontology server and it
uses a Fisher’s exact test for deriving P-values.
Methods
Curated dataset of human proteins involved in 3D
domain swapping
Classification of proteins in 3DSwap knowledgebase
based on SOURCE record from PDB and subsequent
mapping using SIFTS annotations revealed that 75 struc-
tures out of 293 structures reported in 3DSwap were
from Homo sapiens. A cursory look at 3DSwap database
for the taxonomic spread would indicate that the largest
fraction was from humans (25.6%) (Figure 2). We used
literature-curated structures from 3DSwap database with
delineated ‘hinge’ and ‘swapped’ regions for the analysis
in (see Additional file 1: Supplementary Table 1) for list
of proteins used in this study). 75 PDB identifiers were
mapped to UNIPROT and KEGG database identifiers
using Protein ID cross-reference (PICR) service and cus-
tom Perl scripts [82]. Out of the 75 curated protein
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structures with 3D domain conformation retrieved from
3DSwap knowledgebase, 45 proteins were unique (See
Table 1). Human proteins from our curated dataset had
several redundant structures. To avoid potential func-
tional bias, only unique human proteins (45/75 struc-
tures) were used in this analysis. Graphical summary of
the bioinformatics pipeline employed in this study is
depicted in Figure 3.
Enrichment analysis of human proteins involved in 3D
domain swapping
Protein domain enrichment analysis was performed
using DAVID [81]. KEGG pathway analysis was
performed using SubPathwayMiner [83] and Disease
Ontology analysis was performed using Functional Dis-
ease Ontology server [61,62].
Protein domain enrichment analysis
To perform protein domain enrichment analysis,
domains were identified in proteins involved in 3D
domain swapping and a list of protein domains was
obtained. This list of protein domains was compared
against a reference dataset of protein domains associated
with complete human proteome. Protein domain enrich-
ment analysis was performed to understand statistically
significant, conserved, functional modules associated
with proteins involved in 3D domain swapping. Dataset
of 45 Uniprot identifiers were used for protein domain
enrichment analysis using Pfam annotations. DAVID
version 6.7 with default settings was used for the
analysis.
Gene ontology enrichment analysis
GO term enrichment analysis in this study was per-
formed using Ontologizer 2.0, a multifunctional tool for
GO term enrichment analysis. Ontologizer was selected
Figure 2 Taxonomic (a) and species (b) level distribution of proteins in swapped conformation from 3DSwap knowledgebase.
Table 1 Enriched Pfam domains associated with proteins
involved in 3D domain swapping
Pfam identifier Pfam Description P-value
PF07714 Protein tyrosine kinase 3.0E-6
PF00031 Cystatin domain 1.1E-5
PF01463 Leucine rich repeat C-terminal domain 1.9E-3
PF00625 Guanylate kinase 3.3E-4
PF07679 Immunoglobulin I-set domain 6.6E-3
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due to the improved statistical approximation methods
incorporated in it. A brief description of the method is
provided here. Generic GO enrichment tools calculate
the enrichment of a GO term with respect to the list of
genes in the dataset and the background population
using the probability of drawing the same or higher
number of genes annotated to a given term. This basic
concept was implemented using statistical test involving
the upper tail of the hypergeometric distribution or one-
tailed Fisher’s exact test. Such methods do not consider
relationships between the annotation terms. GO is
defined as a directed acyclic graph (DAG), with various
levels of relationships between the terms. Due to DAG
architecture of GO, a gene or gene product annotated
with a term x is also annotated to all parent terms of x,
and this often leads to false enrichment calculations.
Such relationships (for example: is a, part of, has part,
regulates) were taken into account in Ontologizer 2.0
using parent-child inheritance concepts [84]. Detailed
description about the statistical method implemented in
the Ontologizer 2.0 can be found elsewhere [68,84].
Dataset consisting of 45 Uniprot identifiers were used
for species (Homo sapiens) specific GO enrichment ana-
lysis and pathway analysis. GO enrichment analysis was
performed using the following parameters using Ontolo-
gizer 2.0: Gene Ontology annotations were derived from
human-specific annotation data (gene_association.goa_-
human) [58], multiple testing correction was set to
“Bonferroni correction” method, enrichment calculation
was set to Parent-child-Intersection, re-sampling step
was set to 1000. Gene Ontology was defined using
33,738 terms and 59,508 relations recorded in the
gene_ontology.obo file (downloaded on February 2011)
were used for the analysis. Background population for
statistical tests was defined using 18,257 proteins
encoded in the human genome with Gene Ontology
annotations.
KEGG based pathway enrichment analysis of proteins in
human proteome with swapped conformation
Pathway enrichment analysis using KEGG pathway
annotations were performed to understand the role of
proteins in 3D domain swapping conformation in var-
ious biological pathways. UNIPROT Identifiers were
mapped to Entrez gene identifiers using custom Perl
scripts and used as the input in R package SubPathway-
Miner [83] for pathway enrichment analysis. Pathways
associated with these proteins were obtained from
KEGG pathway database and compared to a reference
database of full list of proteins and its corresponding
pathways annotated in KEGG databases.
Disease enrichment analysis of proteins in swapped
conformation using disease ontology
The disease ontology tem enrichment analysis was per-
formed using Functional Disease Ontology server [62].
List of 45 human genes mapped to UNIPROT Identi-
fiers were mapped to Entrez gene identifiers using cus-
tom Perl scripts. List of Entrez identifiers were used as
input for Disease Ontology enrichment to understand
the role of the human proteins with swapped conforma-
tion in various biological pathways. Out of 45 genes in
the list, 35 were found to be associated with at least one
disease. Briefly, the disease association of each gene in
the human genome was annotated using the Disease
Ontology and peer-reviewed evidence from Gene
Related Information into Function (GeneRIF) [61,62,85].
A condensed version of the Disease Ontology, Disease
Figure 3 Bioinformatics pipeline employed to derive functional, pathway and diseases associations of proteins involved in 3D domain
swapping.
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Ontology Lite [61], was used for the statistical analysis.
Similar to Gene Ontology analysis, the significance of
each disease association was evaluated using Fisher’s
exact test.
Results
3D domain swapping is a structural mechanism
employed by a variety of protein structures to form oli-
gomeric assemblies. These oligomers were often asso-
ciated with aggregation diseases or proteinopathies in
humans. Parkinson’s diseases and Alzheimer’s diseases
are two major neurodegenerative diseases due to pheno-
typic impact of 3D domain swapping. Hitherto, no com-
prehensive study has been reported to analyze the
impact of all proteins involved in 3D domain swapping
from a whole proteome-wide or genome-wide perspec-
tive due to unavailability of a well-defined, curated data-
set. We performed the initial investigation of proteins
involved in 3D domain swapping in the level of protein
domains, Gene Ontology, KEGG pathways and Disease
Ontology. Our approach helped to understand enriched
protein domains, Gene Ontology terms, biological path-
ways and Disease Ontology terms mediated by these
proteins and their role in mediating various human
diseases.
Statistically significant protein domains associated with
swapped proteins in the human proteome is provided
(Table 1), GO terms (Tables 2, 3, 4), KEGG pathways
(Table 5) and DO terms (Table 6), associated with
swapped proteins encoded in the human proteome, are
provided. Critical aspects of statistically significant evolu-
tionarily conserved domains, GO terms, KEGG pathways
and DO terms associated with human proteins in
swapped conformation are summarized in the ‘Discus-
sion’ section.
Proteins involved in 3D-domain swapping represents a
large collection of proteins with a variety of functional
and regulatory roles in the cell. Due to limitation in
crystallizing structures in the swapped conformation,
currently available repertoire of proteins in the swapped
conformation may represent only a small fraction of
proteins that may perform its molecular role via 3D
domain swapping. Machine learning algorithms and
computational approaches may help to predict more
proteins with features of 3D domain swapping [11,52].
Here we discuss primary insights obtained from the
initial investigation of proteins involved in 3D domain
swapping. Present results from the human proteome
indicates an important paradigm that future drug design
studies, focusing on various disease categories or path-
ways associated with 3D domain swapping, should con-
sider the structural implications of this important
structural mechanism and associated mechanisms like
macromolecular crowding and protein aggregation.
Functional repertoire of proteins involved in 3D domain
swapping
Protein domain enrichment analysis reveals that five
protein domain families were enriched in the dataset
(See Table 1). These include protein tyrosine kinase
Table 2 Statistically significant Biological Process terms
from GO term enrichment analysis
GO ID GO term P-value
GO:0048518 Positive regulation of biological process 0.002
GO:0016032 Viral reproduction 0.002
GO:0048519 Negative regulation of biological process 0.005
GO:0009987 Cellular process 0.006
GO:0040007 Growth 0.008
GO:0018126 Protein amino acid hydroxylation 0.008
GO:0032501 Multicellular organismal process 0.009
GO:0035110 Leg morphogenesis 0.01
GO:0007154 Cell communication 0.01
GO:0016271 Tissue death 0.011
GO:0051704 Multi-organism process 0.014
GO:0090046 Regulation of transcription regulator activity 0.014
GO:0050896 Response to stimulus 0.015
GO:0044403 Symbiosis, encompassing mutualism through
parasitism
0.015
GO:0001775 Cell activation 0.016
GO:0065007 Biological regulation 0.017
GO:0023052 Signaling 0.019
GO:0032502 Developmental process 0.021
GO:0034465 Response to carbon monoxide 0.021
GO:0014071 Response to cycloalkane 0.023
GO:0006793 Phosphorus metabolic process 0.023
GO:0051098 Regulation of binding 0.026
GO:0000003 Reproduction 0.032
GO:0045342 MHC class II biosynthetic process 0.033
GO:0001816 Cytokine production 0.037
GO:0008356 Asymmetric cell division 0.037
GO:0046417 Chorismate metabolic process 0.038
GO:0030431 Sleep 0.038
GO:0048610 Reproductive cellular process 0.039
GO:0007610 Behaviour 0.043
Table 3 Statistically significant Cellular Component terms
from GO term enrichment analysis
GO ID GO term P-value
GO:0005802 Trans-Golgi network 0.002
GO:0071944 Cell periphery 0.004
GO:0005737 Cytoplasm 0.009
GO:0045121 Membrane raft 0.024
GO:0048786 Presynaptic active zone 0.05
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domain, a member of kinase domain family involved in
signal transduction [86], cystatin domain, a member of
cysteine protease inhibitor family [87], leucine-rich
repeat C-terminal domain, an unique motif that med-
iates protein-protein interaction [88], Guanylate kinase,
a key mediator of catalytic reaction that converts adeno-
sine triphosphate (ATP) to adenosine diphosphate
(ADP) and adenosine monophosphate (AMP) [89] and
Immunoglobulin I-set domain found in several cell
adhesion molecules [90]. We noted that significantly
enriched conserved protein domains associated with 3D
domain swapping plays pivotal role in various signaling
pathways, thus it also points the role of domain swap-
ping in multiple signal transduction events.
Statistically significant GO terms associated with swapped
proteins
GO term enrichment analysis revealed that multiple
terms in three different GO categories were associated
with swapped proteins encoded in the human proteome.
This includes 31 GO terms in biological process category
(Table 2), five GO terms in cellular component category
(Table 3) and 12 terms in molecular function category
(Table 4). DAG structure with highlighted GO terms in
biological process (Additional file 1: Figure S1), cellular
compartment (Figure 4) and molecular function (Addi-
tional file 1: Figure S2) categories are provided. Biological
process contains several non-specific and specific GO
terms that point towards functional understanding of the
proteins involved in 3D domain swapping. Top “Biologi-
cal Process” terms include viral reproduction and protein
amino acid hydroxylation. Two cellular transport related
terms under “Cellular Component” category (membrane
raft and trans-Golgi network), along with cytoplasm and
cell periphery, were also found to be associated with
human proteins involved in 3D domain swapping.
Enriched molecular function terms indicate that human
proteins involved 3D domain swapping is involved in
multiple signaling and binding activities including chro-
matin binding, protein kinase activity and protein dimeri-
zation activity. This also indicates specific role of proteins
involved in swapping and its association with mechan-
isms like oligomerization, macromolecular crowding and
aggregation which are considered to be cellular mechan-
isms implicated by 3D domain swapping. GO term
enrichment analysis provided a cursory view of biological
processes, cellular components and molecular functions
associated with 3D domain swapping.
Implications of 3D domain swapping in in biochemical
pathways
Results from pathway enrichment analysis using BioCon-
ductor based SubPathwayMiner package indicates that
proteins in swapped conformation participate in multiple
biological pathways. Results from pathway enrichment
analysis using KEGG annotations are provided in Table 5.
KEGG database classifies the pathways using a top-level
functional hierarchy classification using KEGG-BRITE
hierarchy. According to this hierarchy, human pathways
were classified into six categories (Metabolism, Genetic
Information Processing, Cellular Processes, Organismal
Systems and Human diseases). Current analysis reveals
that proteins with 3Dswap conformations are present in
all six classes, but significantly enriched KEGG pathways
were observed in all classes except the Genetic Informa-
tion Processing. Proteins involved in 3D domain swapping
are observed in multiple subcategories of KEGG pathway
hierarchy (see Figure 5). KEGG pathway analysis indicated
that proteins in the swapped conformation are statistically
significant in four subclasses of human disease class viz.
Cancers, Immune System Diseases, Infectious Diseases
and Neurodegenerative Diseases. Proteins are also
involved in other subclasses of diseases like Cardiovascular
Diseases of KEGG BRITE hierarchy (See Table 5).
Disease implications of proteins involved in 3D domain
swapping
Since KEGG pathways represent biochemical pathways
and disease pathways in a single framework, a further
detailed analysis of human proteins in swapped conforma-
tion was performed using a dedicated ontology that
defines human diseases. Functional disease ontology anno-
tation tool that uses Disease Ontology-derived “Disease
Ontology-lite” and GeneRIFs were used in this analysis
due to the brevity of the terms and availability of signifi-
cant gene-disease association data. Enrichment analysis
using disease ontology provided a detailed overview of the
statistically significant association between gene-products
in the swapped conformation with various disease cate-
gories. Using the current subset of data, five major classes
Table 4 Statistically significant Molecular Function terms
from GO term enrichment analysis
GO ID GO term P-value
GO:0060089 Molecular transducer activity 0.008
GO:0003682 Chromatin binding 0.008
GO:0042802 Identical protein binding 0.011
GO:0019838 Growth factor binding 0.011
GO:0046983 Protein dimerization activity 0.011
GO:0004713 Protein tyrosine kinase activity 0.013
GO:0019144 ADP-sugar diphosphatase activity 0.02
GO:0004883 Glucocorticoid receptor activity 0.023
GO:0030545 Receptor regulator activity 0.035
GO:0050998 Nitric-oxide synthase binding 0.047
GO:0001871 Pattern binding 0.048
GO:0070851 Growth factor receptor binding 0.049
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of diseases were observed in the disease Ontology-based
enrichment analysis as follows: cancer (prostate cancer,
thyroid cancer, breast cancer and neoplasm metastasis),
diseases of the respiratory or pulmonary system (asthma,
bronchial hyperreactivity, pulmonary alveolar proteinosis),
degenerative diseases of the central nervous system
(Amyotrophic lateral sclerosis, Parkinson’s Disease), vascu-
lar disease (atherosclerosis, hypertension) and encephalitis
(rabies). Neurodegenerative diseases are well-known to
have strong association with 3D domain swapping, but
insights into other diseases indicates that there could be
more proteins with disease association and 3D domain
swapping, beyond the currently well-known group of con-
formational diseases. Detailed table with Disease Ontology
term (disease), genes associated with each disease and
P-value for the association is provided in Table 6. Five of
the significantly enriched diseases in the dataset and the
genes associated with the diseases are provided as a net-
work (Figure 6). Network is defined using genes as nodes
and disease shared between the genes are considered as
common edge between two genes. Disease ontology is use-
ful to map disease relationships across human genes and






hsa05200 Pathways in cancer 0.000 Human Diseases; Cancers
hsa04722 Neurotrophin signaling pathway 0.000 Organismal Systems; Nervous System
hsa05144 Malaria 0.000 Human Diseases; Infectious Diseases
hsa04630 Jak-STAT signaling pathway 0.000 Environmental Information Processing; Signal Transduction
hsa05120 Epithelial cell signaling in Helicobacter pylori
infection
0.000 Human Diseases; Infectious Diseases
hsa05211 Renal cell carcinoma 0.000 Human Diseases; Cancers
hsa04510 Focal adhesion 0.001 Cellular Processes; Cell Communication
hsa04660 T cell receptor signaling pathway 0.001 Organismal Systems; Immune System
hsa05310 Asthma 0.002 Human Diseases; Immune System Diseases
hsa04060 Cytokine-cytokine receptor interaction 0.002 Environmental Information Processing; Signaling Molecules and
Interaction
hsa05020 Prion diseases 0.002 Human Diseases; Neurodegenerative Diseases
hsa05330 Allograft rejection 0.003 Human Diseases; Immune System Diseases
hsa00620 Pyruvate metabolism 0.003 Metabolism; Carbohydrate Metabolism
hsa04672 Intestinal immune network for IgA production 0.005 Organismal Systems; Immune System
hsa05320 Autoimmune thyroid disease 0.006 Human Diseases; Immune System Diseases
hsa05110 Vibrio cholerae infection 0.006 Human Diseases; Infectious Diseases
hsa05221 Acute myeloid leukemia 0.006 Human Diseases; Cancers
hsa04144 Endocytosis 0.008 Cellular Processes; Transport and Catabolism
hsa05218 Melanoma 0.009 Human Diseases; Cancers
hsa05100 Bacterial invasion of epithelial cells 0.009 Human Diseases; Infectious Diseases
hsa05220 Chronic myeloid leukemia 0.010 Human Diseases; Cancers
hsa04520 Adherens junction 0.010 Cellular Processes; Cell Communication
hsa00400 Phenylalanine, tyrosine and tryptophan
biosynthesis
0.010 Metabolism; Amino Acid Metabolism
hsa04664 Fc epsilon RI signaling pathway 0.012 Organismal Systems; Immune System
hsa05222 Small cell lung cancer 0.013 Human Diseases; Cancers
hsa04012 ErbB signaling pathway 0.014 Environmental Information Processing; Signal Transduction
hsa04210 Apoptosis 0.014 Cellular Processes; Cell Growth and Death
hsa04540 Gap junction 0.015 Cellular Processes; Cell Communication
hsa04010 MAPK signaling pathway 0.018 Environmental Information Processing; Signal Transduction
hsa05146 Amoebiasis 0.020 Human Diseases; Infectious Diseases
hsa04360 Axon guidance 0.029 Organismal Systems; Development
hsa04530 Tight junction 0.031 Cellular Processes; Cell Communication
Statistically significant associations are highlighted in bold
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diseases. To expand this disease association to clinically
relevant information, we curated the disease ontology
terms associated with 3D domain swapping to derive the
associated International Classification of Diseases - 9
(ICD-9) codes. Diseases under the following ICD-9 codes
001-139 (infectious and parasitic diseases), 140-239: (neo-
plasms), 320-359 (diseases of the nervous system), 390-
459: diseases of the circulatory system, 460-519 (diseases
of the respiratory system). This further helped to under-
stand major classes of clinically relevant disease pheno-
types mediated by a unique molecular mechanism.
Discussion
Domain swapping is a key pathophysiological mechanism
mediating conformational disease. A detailed account of
functional repertoire, molecular pathways and spectrum
of diseases affected by this mechanism remains elusive.
We used enrichment calculations to understand the
aspects using a curated dataset of proteins involved in 3D
domain swapping. Our analysis was performed using a
dataset of 45 unique human proteins derived from
3DSwap knowledgebase [53]. This dataset will be grow-
ing in the future as structural characterization of human
proteins involved in domain swapping is rapidly increas-
ing. Numerous structures are being identified and more
proteins with swapped conformation may found to be
associated with domain swapping. Performing analysis
using the approaches we employed in the future may
help to identify additional protein domains, Gene Ontol-
ogy terms, molecular pathways and human diseases.
Due to oligomeric features of swapping, earlier studies
have indicated that 3D domain swapping plays a crucial
role in conformational diseases or deposition diseases
and proteinopathies. There was limited insight on struc-
ture-function relationship of proteins involved in domain
swapping due to unavailability of a large dataset to objec-
tively analyze functional or disease implications impli-
cated by 3D domain swapping. Proteins encoded in the
human genome and reported to be involved in 3D
domain swapping were analyzed in detail to understand
the role of gene products in various classes of diseases,
beyond conformation diseases or proteinopathies. Map-
ping and enrichment analysis of human proteins involved
in 3D domain swapping to KEGG pathways in ‘disease’
class and Disease Ontology indicates that these proteins
play a significant role in various other diseases categories
along with well-known neurodegenerative or conforma-
tional diseases.
Availability of genome-scale sequence data and annota-
tions were considered as the ideal resource for gaining
new insights from a plethora of biological data. Structural
mechanisms can gain new insights about the functional
aspects by mapping and database-wide enrichment analy-
sis using annotations. In a similar way, functional mechan-
ism may also gain new insight by using knowledge-based
approaches employed in this study. In summary, the pre-
sent study reports the application of knowledge-based
approaches to understand new functional insights about a
structural mechanism. Starting from an initial dataset of
protein structures, the present study shows the importance
and impact of the data integration and data mining to
Table 6 Disease ontology terms associated with proteins
involved in 3D domain swapping.
DO Term Genes P-value
Asthma IL10, TJP1, BCL2L1, IL5 0.001
Amyotrophic lateral
sclerosis
MET, DCTN1, CST3 0.001




Dental plaque IL10, TJP1, BCL2L1 0.002
Prostate cancer IL10, NCOA2, GLO1,
SERPINC1, CST3
0.002
Fatty liver MET, IL10 0.003
Atherosclerosis NOD1, IL10, EPHX2, CST3 0.003
Rabies RNASE1, BCL2L1, SERPINC1 0.004
Parkinson disease IL10, EPHX2, BCL2L1 0.004
Thyroid cancer IL10, TJP1 0.023
Neoplasm metastasis IL10, RNASE1, CST3 0.024
Hypertension IL10, EPHX2, CST3 0.028
Breast cancer IL10, NCOA2, CSTA, CST3 0.05
Lung cancer IL10, CSTA, CSTB 0.057
Adenovirus infection PTK2, BCL2L1 0.072
Abortion NOD1, IL10 0.085
Autistic disorder MET, GLO1 0.096
Kidney disease PTK2, SERPINC1 0.101
Kidney failure IL10, CST3 0.128
Enteritis NOD1, IL10 0.142
Autoimmune disease IL10, BCL2L1 0.148
Systemic scleroderma MET, IL10 0.173
Ulcerative colitis NOD1, IL5 0.18
Multiple sclerosis GLO1, BCL2L1 0.184
Infection NOD1, IL10 0.266
Dermatitis CSTA, IL5 0.294
Cancer MET, PTK2, EPHX2, BCL2L1 0.329
Lupus erythematosus IL10, PTK2 0.378
Melanoma IL10, TJP1 0.41
Alzheimer’s disease IL10, CST3 0.713
Embryoma IL10, CST3 0.99
Rheumatoid arthritis BCL2L1, CST3 0.99
Colon cancer NOD1, TJP1 0.99
Leukemia IL10, NCOA2 0.99
Diabetes mellitus TJP1, CST3 0.99
Statistically significant associations are highlighted in bold
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derive biologically relevant interpretations of global trends
of a structural mechanism from sequence, functional and
disease perspective. Further new insights are obtained
from a translational perspective by focusing on proteins
involved in 3D domain swapping in the human genome.
3D domain swapping is a unique phenomenon and may
affect availability of active sites and binding sites required
to impart the biological function depending on the
swapped conformation. Perhaps, future drug design stu-
dies should consider these important aspects while devel-
oping therapeutics for various disease categories where 3D
domain swapping is observed.
Clinical relevance of 3D domain swapping
In the current era of personal genomes and network medi-
cine, clinical and therapeutic approaches are utilizing inte-
grated approaches for the understanding of disease states
and pathophysiological mechanisms. Complex disease
states are often triggered by perturbations in multiple
pathways by multiple genes [91-94]. Protein structures
and structural mechanisms play an important role in the
phenotypic impact of various diseases and signaling path-
ways [95-101]. Protein structural information is routinely
utilized to identify drug targets that will help in develop-
ment of effective drugs [102-104]. New approaches will be
Figure 4 Gene Ontology enrichment analysis (Cellular Component) using unique human proteins from the dataset. Colored nodes
indicate enriched terms associated with proteins involved in 3D domain swapping.
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Figure 5 Comparison of KEGG BRITE hierarchies in KEGG database and proteins from the human dataset mapped to KEGG BRITE
hierarchy. HD = Human Diseases, OS = Organismal Systems; CP = Cellular Processes; EIP = Environmental Information Processing; GIP = Genetic
Information Processing and Met = Metabolism.
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required to target proteins or biochemical pathways with
proteins in the swapped conformation. Our study illus-
trates the application of biological and biomedical enrich-
ment tools, ontologies and annotations to understand
functional role and disease implications of an important
structural mechanism from the global perspective of
human proteome.
Insights obtained from our disease ontology analysis
indicates that 3D domain swapping is not just confined to
neurodegenerative diseases, proteins in swapped confor-
mation play a significant role in several other classes of
diseases like cancer, vascular disease, pulmonary disease
etc. Enrichment results discussed in this paper will be use-
ful in such studies in the future from biochemical, func-
tional, structural and therapeutic perspective. Our analysis
also indicates that further genome-specific analysis of pro-
teins involved in 3D domain swapping, using comparative
genome analysis framework, may also add further under-
standing of functional, structural and pathophysiological
manifestations of 3D domain swapping.
Conclusion
3D domain swapping is an important structural mechan-
ism associated with a diverse set of proteins involved in
multitude of biological processes and molecular functions
and diseases including proteinopathies. This phenom-
enon is often studied from the perspective of protein
structure and its impact on biological pathways, correla-
tions with biological functions and association with
classes of diseases other conformational diseases were
largely unknown. We performed a knowledge-based ana-
lysis of human proteins involved in 3D domain swapping
to find the key functions, pathways and diseases asso-
ciated with 3D domain swapping. Our study was limited
to 45 unique proteins involved in 3D domain swapping.
3D domain swapping is a functionally relevant phenom-
enon due to its primary role in protein oligomerization;
proteins with swapped oligomeric states are being identi-
fied on a regular basis using crystallography experiments.
Effective algorithms that can predict swapping from
structural and sequence information may also help to
identify more proteins in swapped confirmation. As more
proteins are being characterized in swapped conforma-
tion, performing such knowledge-based analysis using
new proteins, improved annotations and enhanced ontol-
ogies may reveal additional functional classes, pathways
and disease. In summary, we showed results from an
initial investigation to understand conserved protein
Figure 6 Disease Ontology term - gene network derived from Disease Ontology enrichment analysis using human proteins involved in
3D domain swapping.
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domains, functional repertoire, pathways and diseases
mediated by 3D domain swapping in human proteome.
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